The role of mitoxantrone in the treatment of indolent lymphomas

Oncologist

Volumn 10, Issue 2, 2005, Pages 150-159

  Hagemeister, Fredrick ^a   Cabanillas, Fernando ^b   Coleman, Morton ^c   Gregory, Stephanie A ^d   Zinzani, Pier Luigi ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Auxilio Muto Cancer Center   (Puerto Rico)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Combination therapy; Indolent lymphoma; Mitoxantrone; Progression free survival; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE PHOSPHATE; FLUOROURACIL; MITOXANTRONE; PREDNISONE; RITUXIMAB; THIOTEPA; VINCRISTINE; VINCRISTINE SULFATE;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TOLERANCE; FOLLICULAR LYMPHOMA; HERPES ZOSTER; HUMAN; LYMPHOMA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; SURVIVAL ANALYSIS; VIDARABINE;

EID: 13844321910     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-2-150     Document Type: Article

References (37)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-3918.
2. Armitage JO, Weisenburger D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 1998;16:2780-2795.
3. American Cancer Society. Cancer Facts and Figures 2004. NCI SEER program. Available at http://www.cancer.org/downloads/ STT/CAFF_finalPWSecured.pdf. Accessed November 24, 2004.
4. Vose JM, Chiu BC, Cheson BD et al. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Hematology (Am Soc Hematol Educ Program) 2002:241-262
5. McLaughlin P. Progress and promise in the treatment of indolent lymphomas. The Oncologist 2002;7:217-225.
6. Velasquez WS, Lew D, Grogan TM et al. Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501. J Clin Oncol 2003;21:1996-2003.
7. Liu Q, Fayad L, Hagemeister FB et al. Stage IV indolent lymphoma: 25 years of treatment progress. Blood 2003;102:398a, abstract 1446.
8. McLaughlin P, Rodriguez MA, Hagemeister FB et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 2003;102:564,abstract 2269.
9. Jiang Y, McLaughlin P, Thomaides A et al. Quantification and monitoring of the T(14;18) translocation copy number by real-time PCR in patients with follicular lymphoma treated with FND plus concurrent or delayed rituximab. Blood 2003;102:1444a.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, v.1.2004. Non-Hodgkin's Lymphoma. Jenkintown, PA: NCCN, 2004. Available at http://www.nccn.org. Accessed November 24, 2004.
11. López-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 1998;91:2955-2960.
12. Wallace RE, Murdock KC, Angier RB et al. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl) amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 1979;39:1570-1574.
13. Bennett JM, Muss HB, Doroshow JH et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988;6:1611-1620.
14. Armitage JO. The role of mitoxantrone in non-Hodgkin's lymphoma. Oncology (Huntingt) 2002;16:490-502, 507-508, discussion 511-512, 514.
15. Coltman CA Jr, Coltman TM, Balcerzak SP et al. Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study. Semin Oncol 1984;11(suppl 1):50-53.
16. Gams RA, Bryan S, Dukart G et al. Mitoxantrone in malignant lymphoma. Invest New Drugs 1985;3:219-222.
17. Silver RT, Case DC Jr, Wheeler RH et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol 1991;9:754-761.
18. OSI Pharmaceuticals Medical Information Services. Novantrone and cardiotoxicity. Melville, NY: OSI Pharmaceuticals, 2003.
19. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-794.
20. Hochster HS, Kim KM, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10:28-32.
21. Zinzani PL, Lauria F, Rondelli D et al. Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. Ann Oncol 1993;4:575-578.
22. Gregory SA, Venugopal P, Adler S et al Combined fludarabine, mitoxantrone, and rituximab achieves a high response as initial treatment for advanced low grade non-Hodgkin's lymphoma (LGNHL). Blood 2002;100:362a,abstract 1401.
23. McLaughlin P, Hagemeister FB, Romaguera JE et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262-1268.
24. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-106.
25. Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
26. Czuczman MS, Grillo-Lopez AJ, McLaughlin P et al. Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001;12:109-114.
27. Czuczman MS, Fallon A, Mohr A et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29(suppl 2):36-40.
28. Rambaldi A, Lazzari M, Manzoni C et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-862.
29. DeVita VT Jr, Canellos GP, Chabner B et al. Advance diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975;1:248-250.
30. Dreyling MH, Forstpointner R, Repp R et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma - final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Blood 2003;102:103a,abstract 351.
31. Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654-2661.
32. Lichtman SM, Kolitz J, Budman DR et al. Treatment of aggressive non-Hodgkin's lymphoma in elderly patients with thiotepa, Novantrone (mitoxantrone), vincristine, prednisone (TNOP). Am J Clin Oncol 2001;24:360-362.
33. Coleman M, Furman R, Niesvizky R et al. TOP-M chemotherapy (Thiotepa, Oncovin [Vincristine], Prednisone, Mitoxantrone) plus Ritoximab for marginal zone lymphoma. Blood 2004;104:abstract 4600.
34. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-3928.
35. Bexxar [package insert]. Seattle: Corixa Corp and Philadelphia: GlaxoSmithKline, 2003.
36. Witzig TE, White CA, Gordon LI et al. Final results of a randomized controlled study of the ZevalinTM radioimmunotherapy regimen versus a standard course of rituximab immunotherapy for B-cell NHL. Blood 2000;96:831a.
37. Zevalin [package insert]. San Diego: IDEC Pharmaceuticals Corp, 2002.